MAGE-A3 mRNA Neoantigen Vaccine
MAGE-A3 mRNA neoantigen vaccine expresses human MAGE-A3 protein and, when packaged into LNP, triggers T-cell responses against MAGE-A3 neoantigens in tumors.
- The description claims that the vaccine can trigger T-cell responses against tumors presenting MAGE-A3 neoantigens.
Specifications
- Synthesis scale
- 100 ug, 500 ug, 1 mg
AI Readiness
Good foundation, but some important product data is still missing.
74%